key: cord-0849188-iz5e90h8
authors: Choi, Hyo‐Geun; Wee, Jee Hye; Kim, So Young; Kim, Joo‐Hee; Il Kim, Hwan; Park, Ji‐Young; Park, Sunghoon; Il Hwang, Yong; Jang, Seung Hun; Jung, Ki‐Suck
title: Association between asthma and clinical mortality/morbidity in COVID‐19 patients using clinical epidemiologic data from Korean Disease Control and Prevention
date: 2020-12-10
journal: Allergy
DOI: 10.1111/all.14675
sha: e6c5aea14cba860a43c936e4ce76e86553068050
doc_id: 849188
cord_uid: iz5e90h8

Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, posing a serious public health problem.

To the Editor, Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, posing a serious public health problem. 1 The prevalence of asthma in COVID-19 patents differs among studies, with 0.0% reported in Wuhan, China, and markedly higher prevalence rates of 17% and 14% reported in the United States (US) and the United Kingdom (UK), respectively. [2] [3] [4] Data from the UK showed that asthma was a risk factor for severe COVID-19; however, another study from the United States showed no association between asthma and severe disease, suggesting that it is still unclear whether asthma is a risk factor for a poor prognosis. [5] [6] [7] Given the variability in the reports analyzing the impact of underlying asthma on the prevalence and severity of COVID-19, there is a need to better characterize the relationship between asthma and COVID-19. The Korea Centers for Disease Control and Prevention (KCDC) has collected clinical data from hospitalized patients with mild to critical COVID-19 nationwide using a standardized clinical record form. 8 Using this dataset, we evaluated the association between a history of asthma and mortality and morbidity related to COVID-19. A Cox proportional hazards regression model was used for mortality, and a linear regression model was used for morbidity scores.

In this study population, 2.3% (n = 96) of the patients were diagnosed with comorbid COVID-19 and asthma, while most (n = 3,961) did not have asthma ( Table 1 ). The mortality rate was 8.3% (8/96) in patients with asthma and 3.0% (118/3,961) in those without asthma (P = .009). The relative HR for mortality in participants with asthma compared with those without asthma was 2.48 (95% CI = 1.21-5.08, P = .013). After adjustment for multiple variables, the risk of mortality was 2.20 (95% CI = 1.02-4.76, P = .045) in patients with asthma compared with those without asthma ( Table 2 ). Subgroup analyses based on past medical history showed that among the patients with asthma, those with heart failure and chronic heart disease had an elevated risk of mortality (HR = 31.61, 95% CI = 4.36-229.05, P < .001; HR = 4.68, 95% CI = 1.30-16.84, P = .018, respectively, Table S1 ). To assess the effect of asthma on the clinical morbidity due to COVID-19, the maximum morbidity score was obtained, and this score was used to calculate the EV for morbidity. COVID-19 patients with asthma had a higher maximum morbidity score than those without asthma (EV = 0.44, 95% CI = 0.16-0.73, P = .003); participants with asthma ranked 0.44 points higher than participants without asthma (Tables S2 and S3 ).

These data differ from those reported in previous studies, possibly because of the different healthcare systems in each country and the different characteristics of the study participants. Earlier in 2020, many countries lacked sufficient hospital beds and physicians; however, the initial peak surge in cases during the COVID-19 pandemic did not exceed the capacity of the healthcare system; during this period, ~10,000 patients were infected among ~50,000,000

Koreans. The registry used in this study includes COVID-19 patients across the spectrum of disease severity, unlike other studies, which mostly included hospitalized patients with severe disease. 5, 9 As all COVID-19 patients are isolated, even those with mild cases, we postulate that the impact of host factors such as underlying diseases may be relatively greater on the outcomes. However, we could not analyze the effect of asthma-related factors such as inflammatory markers, lung function, and medications due to the limited availability of the relevant data. Specifically, severe or intrinsic asthma is considered a risk factor for a poor prognosis in patients with COVID-19; nevertheless, supporting studies are still limited and inconclusive. 7, 8, 10, 11 Our study provides strong evidence that asthma is associated with an increased risk of mortality and worse clinical outcomes of COVID-19. However, considering that asthma is a heterogeneous disease, further studies investigating the effects of asthma severity and asthma endophenotypes should be performed in a large cohort.

We acknowledge all the healthcare workers involved in the diagnosis 

The authors declare that they have no conflicts of interest. The model was adjusted for age, sex, obesity, systolic blood pressure, diastolic blood pressure, heart rate, temperature, diabetes, hypertension, heart failure, chronic heart disease, chronic obstructive pulmonary disease, chronic kidney disease, cancer, chronic liver disease, rheumatic or autoimmune disease, and dementia.

TA B L E 2 Crude and adjusted hazard ratios (95% confidence interval) for death in asthma and nonasthma groups with subgroup analyses

Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI)

Association of asthma and its genetic predisposition with the risk of severe COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States

Factors associated with COVID-19-related death using OpenSAFELY

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak

Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

COVID-19 in a patient with severe asthma treated with Omalizumab